Memantine Solution
Product Images NDC 60505-6162

Product Visual Gallery

This gallery contains 23 technical images submitted to the FDA as part of the official labeling for Memantine (NDC 60505-6162). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Apotex Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Components (Components)

Illustration showing the components of MEMANTINE Hydrochloride Oral Solution 2 mg/mL by Apotex Corp. Included are the product carton and bottle labeled with strength, a packaged oral dosing syringe, a packaged oral syringe tip, and medication instruction cards or leaflets.*

FDA Label Image

Figure1 (Figure1)

A line graph showing the mean change from baseline in ADCS-ADL scores over 28 weeks of treatment comparing Memantine HCl and placebo. The x-axis represents weeks of treatment, and the y-axis represents mean change in score with standard error bars. Two lines depict clinical improvement or decline, with Memantine HCl showing less decline compared to placebo over time.*

FDA Label Image

Figure2 (Figure2)

A line graph comparing the cumulative percentage of patients versus the ADCS-ADL change from baseline for Memantine HCl and placebo groups. The x-axis shows negative change values from +10 to -25, and the y-axis shows cumulative percentages from 0% to 100%. Data are represented by circles for Memantine HCl and squares for placebo.*

FDA Label Image

Figure3 (Figure3)

A line graph depicting the mean change from baseline in SIB (Severe Impairment Battery) score over 28 weeks of treatment. Two groups are charted: one receiving placebo and the other memantine hydrochloride. The y-axis represents mean change with clinical improvement and decline indicated, while the x-axis represents weeks of treatment. The memantine HCl group shows less decline compared to placebo over time.*

FDA Label Image

Figure4 (Figure4)

A line graph depicting the cumulative percentage of patients on the vertical axis and SIB (Severe Impairment Battery) change from baseline on the horizontal axis. Two lines compare placebo (black squares) and Memantine HCl (open circles), showing patient response distribution across SIB score changes.*

FDA Label Image

Figure5 (Figure5)

A line graph showing the mean change from baseline in ADCS-ADL score over 24 weeks of treatment. Two treatment groups are compared: Placebo/Donepezil and Memantine HCl/Donepezil. The graph includes error bars representing SEM, with clinical improvement and decline indicated by dashed horizontal lines.*

FDA Label Image

Figure6 (Figure6)

A cumulative percentage of patients plot comparing two treatment groups: Placebo/Donepezil and Memantine HCl/Donepezil. The x-axis shows ADCS-ADL change from baseline, and the y-axis shows the cumulative percentage of patients. The graph depicts patient response distributions for these groups.*

FDA Label Image

Figure7 (Figure7)

A line graph comparing mean change from baseline in SIB score over 24 weeks of treatment for two groups: Placebo/Donepezil and Memantine HCl/Donepezil. The y-axis shows mean change (±SEM) ranging from -4 to 4, indicating clinical improvement and decline, while the x-axis represents weeks of treatment. Memantine HCl/Donepezil shows improvement, whereas Placebo/Donepezil trends toward decline after initial weeks.*

FDA Label Image

Figure8 (Figure8)

A cumulative percentage of patients chart showing SIB (Severe Impairment Battery) change from baseline for two groups: Placebo/Donepezil and Memantine HCl/Donepezil. The x-axis represents SIB change from baseline, ranging from 20 to -30, and the y-axis shows the cumulative percentage of patients from 0 to 100%. The Memantine HCl/Donepezil group is represented by circles and the Placebo/Donepezil group by squares, showing a distribution trend of patient responses.*

FDA Label Image

Step1 (Step1)

An instructional illustration showing a hand holding a dosing syringe being inserted into an oral medication bottle or pouch. This likely demonstrates how to draw the liquid medication dose from the container for oral administration.*

FDA Label Image

Step10 (Step10)

An instructional black and white illustration showing a hand stirring a liquid in a glass with a spoon or stirrer. This diagram likely represents proper preparation or administration of an oral solution medication.*

FDA Label Image

Step11 (Step11)

MEMANTINE 2 mg/mL oral solution bottle label showing "Memantine Hydrochloride Oral Solution" and strength "2 mg/mL" on a gray and white label. The image depicts a clear round bottle with a child-resistant cap.*

FDA Label Image

Step2 (Step2)

An instructional illustration showing a hand gripping the cap of a bottle and pushing down to open it, demonstrating how to open a child-resistant bottle closure.*

FDA Label Image

Step3 (Step3)

An instructional illustration showing a hand opening a bottle by unscrewing the cap. The image suggests how to properly open the bottle, which may be part of the instructions for the MEMANTINE 2 mg/mL oral solution packaged by Apotex Corp.*

FDA Label Image

Step4 (Step4)

An instructional line drawing showing a person holding a bottle with one hand while using the other hand to press or push down on the cap, indicated by an arrow pointing downward. The image likely demonstrates how to open or close the bottle cap for a medication solution.*

FDA Label Image

Step5 (Step5)

An instructional line drawing showing two hands. One hand is holding a bottle, while the other hand is using a dropper to draw liquid from the bottle. The image likely demonstrates how to use the dropper to measure or dispense the oral solution.*

FDA Label Image

Step6 (Step6)

An instructional illustration showing a person drawing MEMANTINE memantine hydrochloride oral solution from a bottle into an oral syringe. The bottle is held upside down with one hand while the other hand pulls back the syringe plunger to measure the dose. An arrow indicates the motion direction of pulling the plunger.*

FDA Label Image

Step7 (Step7)

An instructional illustration showing a hand holding a dropper or pipette above a small container or vial, demonstrating how to withdraw or dispense liquid from the container. No text or labeling visible.*

FDA Label Image

Step8 (Step8)

An instructional illustration showing a person administering oral medication using an oral syringe directed into the mouth of another individual, demonstrating proper technique for oral solution dosing.*

FDA Label Image

Step9 (Step9)

An instructional illustration showing two hands handling a bottle labeled "Memantine Hydrochloride Oral Solution." One hand grips the bottle while the other hand is turning the cap, demonstrating how to open the bottle. The label text is partially visible on the bottle.*

FDA Label Image

Bottle-label (Bottle Label)

Label for MEMANTINE Memantine Hydrochloride Oral Solution 2 mg/mL by Apotex Corp. The label indicates a 360 mL (12 fl oz) bottle with dosage instructions and storage conditions. The product is for oral use and prescription only, with manufacturing details and bar code visible.*

FDA Label Image

Carton (Carton)

Packaging label for Memantine Hydrochloride Oral Solution 2 mg/mL by Apotex Corp. The label indicates a 360 mL (12 fl oz) solution with prescription use only. It provides storage instructions, inactive ingredients, and manufacturing details for Apotex Inc., Canada, and Apotex Corp., USA.*

FDA Label Image

Structural Formula (Memantine Structure)

Chemical structure of memantine hydrochloride showing its molecular arrangement with amino and hydrochloride groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.